ReviewNature reviews. Endocrinology2018
A Consensus Statement on acromegaly therapeutic outcomes.
Review in Nature reviews. Endocrinology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 284 papers, 9 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
284 citing papers in PubMed, 9 syntheses or guidelines pooled it.
- Efficacy and safety of pharmacologic therapies in acromegaly: a systematic literature review and network meta-analysis.The Journal of clinical endocrinology and metabolism · 2026Pooled it
- Impact of pasireotide on lipid and glucose metabolism in patients with acromegaly: a systematic review and meta-analysis.Journal of endocrinological investigation · 2025Pooled it
- Real-world evidence of effectiveness and safety of pasireotide in the treatment of acromegaly: a systematic review and meta-analysis.Reviews in endocrine & metabolic disorders · 2025Pooled it
- Efficacy and safety of pasireotide treatment in acromegaly: A systematic review and single arm meta-analysis.Pituitary · 2024Pooled it
- Myocardial Mechanics in Acromegaly: A Meta-Analysis of Echocardiographic Studies.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2024Pooled it
- Surgical and non-surgical interventions for primary and salvage treatment of growth hormone-secreting pituitary adenomas in adults.The Cochrane database of systematic reviews · 2024Pooled it
- Recurrent acromegaly: a systematic review on therapeutic approaches.BMC endocrine disorders · 2024Pooled it
- Questionnaire and tools: clinical powerful instrument in acromegaly diagnosis and management.Journal of endocrinological investigation · 2022Pooled it
- State of the Art of Patient-reported Outcomes in Acromegaly or GH Deficiency: A Systematic Review and Meta-analysis.The Journal of clinical endocrinology and metabolism · 2022Pooled it
- Octreotide Subcutaneous Depot for Acromegaly: A Randomized, Double-blind, Placebo-controlled Phase 3 Trial, ACROINNOVA 1.The Journal of clinical endocrinology and metabolism · 2025Trial
- ACROBAT Edge: Safety and Efficacy of Switching Injected SRLs to Oral Paltusotine in Patients With Acromegaly.The Journal of clinical endocrinology and metabolism · 2023Trial
- Comparative effectiveness of endoscopic and microscopic adenoma removal in acromegaly.Frontiers in endocrinology · 2023Trial
- Durable biochemical response and safety with oral octreotide capsules in acromegaly.European journal of endocrinology · 2022Trial
- Patient-reported outcomes in patients with acromegaly treated with pegvisomant in the ACROSTUDY extension: A real-world experience.Pituitary · 2022Trial
- Soluble alpha-klotho as an adjunct biomarker of disease activity in acromegaly: Added value beyond GH and IGF-1.Pituitary · 2026Article
- Postoperative Pituitary MRI Findings in Acromegaly: A Pictorial Review.Diagnostics (Basel, Switzerland) · 2026Review
- Cardiac Resynchronization Therapy With Defibrillator for Acromegalic Cardiomyopathy With Left Bundle Branch Block.JACC. Case reports · 2026Article
- Development and characterization of a long-acting allosteric growth hormone receptor antagonist for acromegaly.Endocrinology · 2026Article
- Can acromegaly be controlled in all cases?Journal of neuroendocrinology · 2026Review
- Phase 1 Study of Paltusotine, a Novel Oral Once‑Daily, Nonpeptide Selective Somatostatin Receptor 2 Agonist, in Healthy Japanese Adults.Clinical pharmacology in drug development · 2026Article
224 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The 11th Acromegaly Consensus Conference in April 2017 was convened to update recommendations on therapeutic outcomes for patients with acromegaly. Consensus guidelines on the medical management of acromegaly were last published in 2014; since then, new pharmacological agents have been developed and new approaches to treatment sequencing have been considered. Thirty-seven experts in the management of patients with acromegaly reviewed the current literature and assessed changes in drug approvals, clinical practice standards and clinical opinion. They considered current treatment outcome goals with a focus on the impact of current and emerging somatostatin receptor ligands, growth hormone receptor antagonists and dopamine agonists on biochemical, clinical, tumour mass and surgical outcomes. The participants discussed factors that would determine pharmacological choices as well as the proposed place of each agent in the guidelines. We present consensus recommendations highlighting how acromegaly management could be optimized in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.